WL
Uploaded byWilliam Lincourt
DOCX, PDF542 views

Professional Expericance

This document summarizes the professional experience of an individual with over 20 years in clinical research and medical affairs in the respiratory field. Some key points: - Current role as Scientific Director of Respiratory Medicine Development at GlaxoSmithKline since 2001, leading clinical development programs and regulatory submissions. - Previous roles included clinical program head and principal clinical research scientist at Glaxo Wellcome from 1994-2001, managing phase IV clinical trials and supporting product launches. - Extensive experience in areas such as asthma, COPD, clinical trials, regulatory submissions, publications, and medical education. - Demonstrated strong communication, project management, and cross-functional skills over long career in drug development and commercial

Embed presentation

Download to read offline
Professional Expericance Glaxo SmithKline Inc. RTP, North Carolina April 2001- Present Scientific Director Respiratory Medicine Development North American Medical Affairs Role requires a strong scientific and commercial understanding of the respiratory market as well as the ability to effectively communicate scientific information and develop clinical programs that support registration and promotion of respiratory medicine. Support US and global strategy for clinical development programs and regulatory submissions of new and marketed respiratory medicines. Develop phase II,-IV clinical studies. Extensive experience in areas of asthma disease progression, asthma management, HPA axis function, and device testing and specifications. Lead USMA Asset Scientist for FF/BREO. Member of FF/BREO asthma MMT and Launch strategy Teams. Member of the US Medical Affairs launch team for Flovent and Advair launches. Experienced in processing clinical and economic data for regulatory submission, publication, and formulary acceptance. Clinical lead for pediatric exclusivity for Ventolin and MDI dose counter programs. Prepare clinical sections of FDA briefing documents, Pediatric Study Plans (PSP) and EU Pediatric Investigation Plans (PIP). Medical Affairs scientist on Bioequivalence/Generic project team. Write, edit or review manuscripts, product monographs, sales training materials and promotional sales aids. Train sales staff and Regional Medical Scientists on key scientific data. Member of MMT, adult and pediatric asthma strategy teams, Clinical Lead for Study Conduct Teams and UMAP/program development working groups. Possess strong communication skills, ability to work across functional groups, knowledge of drug development and commercial as well as a good understanding of the competitive landscape. April 94 – April2001 Glaxo Wellcome, Inc. RTP, North Carolina Clinical Program Head Principal Clinical Research Scientist Respiratory Medical Affairs Project and program level management of phase IV clinical drug studies. Develop novel approaches to support product launch and promotional activities. Manage Contract Research Organizations conducting large multi-center clinical drug trials. Review and interpret clinical data and write/edit study reports, manuscripts, and abstracts. Forecast clinical budgets and manpower needs. Review and edit sales detail aids and physician teaching materials. Aug. 87 - April 94 Bristol-Myers Squibb Inc. Wallingford, Connecticut Senior Clinical Scientist - Infectious Diseases Clinical Scientist - Infectious Diseases Project management, clinical plan administration, protocol development, NDA support and review. Budget and resource negotiations. Supervise clinical trial monitored and
oversee Contract Research Organizations. Worked with 2nd and 3rd generation cephalosporins and anti-virals for claims in adults and children. Area of expertise includes upper and Oct. 83 - Aug. 87 Bristol-Myers Squibb Inc. Pharmaceutical Research Institute Wallingford, Connecticut Research Scientist Pre-clinical characterization of novel Antibiotic compounds. Evaluate data in support of the IND. Supervised one technician. Jan 82 - June 83 University of New York at Buffalo Medical School Buffalo, New York Research Technician - Infectious Diseases Research in the areas of antibiotic resistance, peptidoglycan structure and anaerobic bacterial growth. June 81 - Dec. 81 University of New York College at Buffalo Buffalo, New York Graduate Assistant Department of Biology Research in the area of host-parasite interactions Education Degree: Bachelor of Science in Biology May 1981. Salisbury University, Salisbury, MD 21801 Graduate School, 1981- 1983, State University of New York, College at Buffalo, Buffalo, NY Related Courses PhRMA Asthma Course PhRMA Clinical Study Management Course Effective Presentations Influence Management, Glaxo Wellcome 5-day management Core Technical Writing Management Leadership The Successful Negotiator Matrix Management Project Management Organizations/ Honors Beta Beta Beta National Biology Society, Omicron Delta Kappa National Honor Society Campus Life and Leadership Award- Salisbury University
Publications Manuscripts Fung-Tomc, J.; Lincourt W.; Thater C.; Kessler, R.; “Comparison of the Inhibitory and Bactericidal Activity of Aztreonam and Amikacin against Gram-Negative Aerobic Bacilli.” Annals of Clinical and Laboratory Science, Vol. 18, No. 6: 463-467, 1988. Raphael, G., Lanier, R.,Baker, J., Edwards, L., Rickard, K., Lincourt, W. “A Comparison Of Multiple Doses Of Fluticasone propionate and Beclomethasone dipropionate in subjects with persistent asthma” Journal of Allergy and Clinical Immunology., May 1999 Sorkness, C,. LaForce, C,. Storms, W,. Lincourt, W,. Edwards, L,. Rogenes, P,..“ The Effects of the Inhaled Corticosteroids Fluticasone propionate, Triamcinolone acetonide, and Flunisolide and oral Prednisone on the HPA-axis in Adult Asthmatics,”...Clinical Therapeutics, March 1999 Berger, W., Ford, L,. Mahr, T,. Nathan, R,. Crim, C,. Edwards, Lisa,. Wightman, D,. Lincourt, W,. Rickard, R,. “Efficacy and Safety of Fluticasone propionate 250mcg administered once daily in patients with persistent asthma treated with or without inhlaed corticosteroids.” Annals of Allergy, Asthma and Immunology Vol.89 Number 4, October 2002, pg. 393-399. Keton Sheth, MD; Jonathan A. Bernstein, MD; William R. Lincourt, BS; Kunal K. Merchant, PhD; Lisa D. Edwards, PhD; Courtney C. Crim, MD; Paul M. Dorinsky, MD, “Patient Perceptions of an Inhaled Asthma Medication administered as an Inhalation Powder via the DISKUS®™ or as an Inhalation Aerosol via a Metered Dose inhaler” Annals of Allergy, Asthma, & Immunology. 2003;91:55– 60. Jacqueline R. Carranza Rosenzweig, Lisa Edwards, William Lincourt, Paul Dorinsky and Richard L ZuWallack, “THE EFFECT OF LUNG FUNCTION AND DAILY SYMPTOMS ON ASTHMA QUALITY OF LIFE IN PATIENTS WITH PERSISTENT ASTHMA” Respiratory Medicine (2004) 98, 1157–1165 Courtney Crim, MD; Mark Holmes; Benjamin Lee, PharmD; Robb Cavanaugh; William Lincourt.,Evaluation of Particle Size Distribution of Ventolin HFA Administered via Metered Dose Inhaler With and Without Valved Holding Chambers, Annals of Allergy, Asthma, & Immunology. 94(1):80-85, January 2005. Nancy K. Ostrom, MD, Bruce A. Decotiis, MD, William R. Lincourt, BS, Lisa D. Edwards, Ph.D, Kathleen M. Hanson, BS, Jacqueline R. Carranza Rosenzweig, Pharm.D., Courtney Crim, MD, Comparative Efficacy and Safety of Low-Dose Fluticasone propionate and Montelukast in Children with Persistent Asthma, . Journal of Pediatrics August 2005. Richard L. Wasserman, MD; Ketan Sheth, MD; William R. Lincourt, BS; Nicholas W. Locantore, PhD; Jacqueline Carranza Rosenzweig, Pharm.D; Courtney Crim, MD Real World Assessment of a Metered Dose Inhaler with Integrated Dose Counter. Allergy & Asthma Proceedings 27:486 –492, 2006; .
E.M. KERWIN, M.D., M.M. TARPAY, M.D., K. KIM, M.D., M. J. NOONAN, M.D., W. LINCOURT, B.S., R. TRIVEDI, M.S., A. ELLSWORTH, B.S., A. DAVIS-ALLEN, M.D. Safety and Efficacy of a New Albuterol Hydrofluoroalkane Formulation for Treating Asthma Symptoms in Children 2 to Less than 4 Years of Age Pediatric Asthma, Allergy, and Immunology. Volume 19, Number 2, 2006. pp 81-90. K. SHETH, R. L. WASSERMAN, W. R. LINCOURT, N. W. LOCANTORE, J . CARRANZA- ROSENZWEIG, C. CRIM; Fluticasone propionate/salmeterol hydrofluoroalkane via metered- dose inhaler with integrated dose counter: performance and patient satisfaction Ltd Int J Clin Pract, October 2006, 60, 10, 1218–1224 James A. Hedrick, James W. Baker, Arthur B. Atlas, Aftab A. Naz, William R. Lincourt, Roopa Trivedi, Anna Ellworth and Angela M. Davis; Safety of Daily Albuterol in Infants with a History of Bronchospasm: A Multi-Center Placebo; Controlled Trial, The Open Respiratory Medicine Journal, 2009, 3, 100-106 Mintz M., Gilsenan A.W., Bui C.L., Ziemiecki R., Stanford R.H., Lincourt W., Ortega H;. Predictors of Asthma Control: Results from the Asthma Control Characteristics and Prevalence Survey Study (ACCESS) Current Medical Research and Opinion 2009 25:10 (2523- 2531) William Lincourt, Richard H Stanford, Alicia Gilsenan, Dana DiBenedetti and Hector Ortega; Assessing Primary Care Physician’s Beliefs and Attitudes of Asthma Exacerbation Treatment and Follow-up. The Open Respiratory Medicine Journal, 2010, 4, 9-15 9 Kaashmiri M., Shepard J., Goodman B., Lincourt W.R., Trivedi R., Ellsworth A., Davis A.M. Safety of daily albuterol in infants with a history of bronchospasm: A multi-center placebo controlled trial; Pediatric Emergency Care 2010 26:3 (197-202) Liu A.H., Gilsenan A.W., Stanford R.H., Lincourt W., Ziemiecki R., Ortega H. Status of asthma control in pediatric primary care: Results from the pediatric asthma control characteristics and prevalence survey study (ACCESS) Journal of Pediatrics 2010 157:2 (276-281.e3) Stanford R.H., Gilsenan A.W., Ziemiecki R., Zhou X., Lincourt W.R., Ortega H; Predictors of uncontrolled asthma in adult and pediatric patients: Analysis of the asthma control characteristics and prevalence survey studies (ACCESS). Journal of Asthma 2010 47:3 (257-262) Katial R.K., Bernstein D., Prazma C.M., Lincourt W.R., Stempel D.A. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. Allergy and Asthma Proceedings 2011 32:2 (127-136) Other Publications Murphy, T.; Lincourt, W.; “Studies on Mutants of Clostridium perfringens.” State University of New York Department of Medicine Research Conference, 1983.
Fung-Tomc, J.; Lincourt, W.; Thater, C.; Kolek, B.; Huczkoe, E. Denbleyker, K.; and Kessler, R.; “In Vitro Activity of a New Fluoronapthyridone BMY 40062.” International Conference of Antimicrobial Agents and Chemotherapy, 1988. Jaurequi, L.; Lincourt W.; Doyle, C.; Tenney, J.; and Multi-Center Study Group. “Comparisons of Cefepime (FEP) and Ceftazidime (CAZ) for Treatment of Bacteremia and Sepsis - A Physiologic Analysis of Efficacy.” International Conference of Antimicrobial Agents and Chemotherapy, 1993. McCabe, R.; Farkas, S.; Lincourt W.’ Doyle, C.; and the Cefepime Multi-Center Study Group. “Efficacy Summary of International Experience with Cefepime (FEP) vs. Ceftazidime (CAZ) or Cefotaxime (CTX) for Pneumonia.” International Conference of Antimicrobial Agents and Chemotherapy, 1993. Galant, S.P.; Lincourt, W.; Rogenes, P.; Field, E. A.; Wisniewski, M. “Fluticasone Propionate Aqueous Nasal Spray versus Antihistamines for Sneezing and Nasal Itching.” American College of Allergists and Immunologists, 1994. Kapke, G.; Lincourt, W., “Immunochemical Versus HPLC Measurement of Serum Cortisol During A 6 Hour Cortrosyn Infusion In Steroid Naive Asthmatics” International Conference of the American Thoracic Society, May 1996. LaForce, C., Goldstein, M., Storms, W., Levy, B., Li, J., Littlejohn, T., McCluskey, D., Lincourt, W., Rogenes, P., Schaberg, A., Wisniewski, M., “Comparision of Inhaled Fluticasone Propionate And Flunisolide Effects on The HPA Axis As Assessed By The 6-Hour Cosyntropin Infusion Testing”. The European Resp. Journal, Vol 9, Supplement 23, Sept 1996. Sorkness, C., Howland, W., Stricker, W., Tita, J., Noveck, R., Dockhorn, R., Talbot, S., Lincourt, W., Rogenes, P., Schaberg, A., Wisniewski, M., “Comparision of Inhaled Fluticasone Propionate And Triamcinolone Acetonide Effects on The HPA Axis As Assessed By The 6-Hour Cosyntropin Infusion Testing”. The European Resp. Journal, Vol 9, Supplement 23, Sept 1996. Stroms, W., Howland WC., Sorkness CA., LaForce C., Goldstein , M., Lincourt, WR., Rogenes PR., Schaberg, AE., Edwards, L., “ Fluticasone Propionate, Triamcinolone Acetonide and Flunisolide have similar Effects on the HPA Axis. American Academy of Allergy Asthma and Immunology, March 1997. GD Raphael, JW Baker, P Chervinsky, J Grossman, MF Goldstein, , PR Rogenes, L Edwards, WR Lincourt, “Low Dose Fluticasone Propionate(FP) Is More Effective Than Higher Doses of Beclomethasone Dipropionate (BDP) In Patients With Mild To Moderate Asthma” American Academy of Allergy Asthma and Immunology, March 1998 JJ Murray, B Friedman, P Chervinsky, C Fogarty, JW Baker , PR Rogenes, L Edwards,.WR Lincourt,”Asthma Severity as a Determinant for Selecting Appropriate Doses of Fluticasone Propionate(FP) or Beclomethasone Dipropionate(BDP)” American Academy of Allergy Asthma and Immunology, March 1998
JJ Murray, B Friedman, P Chervinsky, C Fogarty, JW Baker , PR Rogenes, L Edwards, WR Lincourt, “Fluticasone Propionate(FP) Is More Effective Than Higher Doses of Beclomethasone Dipropionate (BDP) In Patients With Moderate Asthma” International Conference of the American Thoracic Society, May 1998 Srebro SH, Rogenes PR, Edwards L, Lincourt WR: Comparison of efficacy and HPA effects of fluticasone propionate versus flunisolide in patients with mild to moderate asthma ;, Am J Respir Crit Care Med 1998; 157 (3): A406 C Crim, WR Lincourt, AL Stevens, TP Shah, LD Edwards, SM Harding, KA Rickard; Once- Daily Low Dose Fluticasone Propionate Diskus as Initial therapy in the Treatment of Adult Subjects with Persistent Asthma - A Subset Analysis of the Clinical Efficacy of Once-Daily dosing in Subjects with Mild-to-Moderate Asthma., American Academy of Allergy Asthma and Immunology, March 2000 Lisa D Edwards, Ken M Kral, James R Johnson, William R. Lincourt, A RETROSPECTIVE DESCRIPTIVE MEDICAL CLAIMS ANALYSIS OF INCREASED MEDICAL RISK IN ASTHMA MANAGEMENT FOR PATIENTS PRESCRIBED MONTELUKAST COMPARED TO FLUTICASONE PROPIONATE, American Academy of Allergy Asthma and Immunology, March 2001 Chervinsky P, Kalberg C, Goode-Sellers S, Edwards L, Lincourt W, Rickard K. A Comparison of Low Dose Fluticasone Propionate and Montelukast in Patients Stratified Based on Baseline Asthma Severity. Amer J Resp Crit Care Med; 163(5):A428, April 2001. Berger WE, Mahr TA, Crim C, Wightman DS, Edwards LD, Lincourt, WR, Rickard KA; Flovent 250mcg Administered Once Daily is Effective Initial Therapy in Patients with Persistent Asthma Currently Treated with Bronchodilators Alone, ACAAI in November 2001 Ford L, Crim C, Lincourt WR, Wightman D, Edwards LD, Rickard KA. Once Daily Low Dose Fluticasone Propionate In The Treatment Of Adult And Adolescent Subjects With Persistent Asthma Currently Using Low Doses Of Inhaled Corticosteroids. (AAAAI March 2002). K. K. Sheth, W. R. Lincourt, L. D. Edwards, P. Dorinsky, C. Crim; Patient Perceptions of an Inhaled Asthma Medication Administered as an Inhalation Powder via the Diskus or as an Aerosol via a Metered Dose Inhaler (AAAAI March 03) J.R.Carranza Rosenzweig, Pharm.D, M.S., L.D. Edwards, Ph.D , W.R .Lincourt, B.S. , R.H. Stanford, Pharm.D. and P.M. Jhingran, Ph.D. CORRELATION BETWEEN SYMPTOMS, LUNG FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH PERSISTENT ASTHMA, (International Conference of the American Thoracic Society May 2003)
N.K.Ostrom, MD , B.A.DeCotiis, MD , W.R.Lincourt, BS , L.D.Edwards, PhD and C. Crim, MD ; A Comparison of Low Dose Fluticasone Propionate and Montelukast in Children 6-12 Years of Age with Persistent Asthma. (International Conference of the American Thoracic Society May 2003) Courtney Crim, MD; Benjamin Lee, PharmD; William Lincourt; Mark Holmes, BSc (Hons ); and Robb Cavanaugh. GlaxoSmithKline, Inc., Research Triangle Park, NC, USA, IN-VITRO COMPARISON OF THE PERFORMANCE OF VALVED HOLDING CHAMBERS (VHC) FOR DELIVERY OF VENTOLIN® HFA INHALATION AEROSOL, (International Conference of the American Thoracic Society, May 2003) Carranza Rosenzweig, J; Lincourt, W ; Edwards, L ; Rickard, K; Cost-efficacy of Fluticasone Propionate Compared To Montelukast in the Treatment of Pediatric Asthma, (ACAAI 2003) W. R. Lincourt, C. Crim, K. M. Hanson, L. D. Edwards; Fluticasone Propionate (FP) was Superior to Montelukast (MON) in Producing at Least a 2-Step Improvement in Asthma Severity in Children 6-12 Years of Age. AAAAI, March 2004 (POSTER #348) C. Crim, M.D. , R. Trivedi , B. Lee , W. Wu, T. Weeks and W. Lincourt; Asthma Exacerbations Associated with Upper Respiratory Tract Infections in Asthmatic Children Under 4 years of Age Treated with Fluticasone Propionate . Poster Presentation at a Thematic Poster Session A53 Asthma Therapy (International Conference of the American Thoracic Society, May 2004) Courtney Crim, William Lincourt, Roopa Trivedi, Anna Ellsworth, Angela Davis-Allen,Ventolin HFA MDI, safety in children 24-<48 months old with asthma-like symptoms AAAAI, March 2005 Poster presentation. K.K. Sheth, MD, MBA , W.R. Lincourt, BS , B.T. Lee, Pharm. D2 , N.W. Locantore, Ph. D and C. Crim, MD; A Study to Evaluate the Handling Performance of Fluticasone Propionate/Salmeterol HFA MDI with Counter in Subjects with Asthma or COPD; American Thoracic Society, May 2005 poster presentation. Crim, Lincourt, Locantore, Rosenzweig, Handling Performance and Patient Satisfaction of a Metered Dose Inhaler(MDI) With Integrated Dose Counter in Patients With COPD. ACCP Chest meeting. ACCP – Poster- Montreal, Quebec, Canada Oct. 29-Nov. 3, 2005 Sheth K, Crim C, Carranza Rosenzweig J, Lincourt W, Locantore. Reliability and Patient Satisfaction with MDI with Dose Counter.Lincourt W, Poster- ACAAI - Anaheim, CA Nov. 5- 7, 2005 Sheth K, Lincourt W, Crim C, , Locantore W, Carranza Rosenzweig J. Patient Satisfaction with Fluticasone Propionate/Salmeterol (FSA) HFA with an Integrated Dose Counter. Poster- ERS - Copenhagen, Denmark Sept.17-21, 2005 Angela Davis, William Lincourt, Roopa Trivedi, et.al. Safety of Ventolin HFA MDI in Children Birth-<24 Months Old with Symptoms of Bronchospasm Presented at the Annual Meeting of American Academy of Allergy, Asthma and Immunology March 3-7, 2006 Miami Beach, FL
Julie Shepard MD* Courtney Crim MD Roopa Trivedi MS William Lincourt BS Anna Ellsworth BS Angela Davis MD Ohio Pediatrics Inc., Huber Heights, OH RESULTS OF A RANDOMIZED CONTROLLED TRIAL ON REPEAT ALBUTEROL DOSING IN ACUTELY WHEEZING CHILDREN <24 MONTHS OLD, Pediatric presented at CHEST: Chest Medicine Wednesday, October 24, 2007 J. Hedrick, M.D., A.M. Davis, M.D., W. Lincourt, B.S., R. Trivedi, M.S., A.Ellsworth, B.S., C. Crim, M.D Cardiac Safety Of Ventolin HFA In Children <48 Months Old.. AAAAI Jan. 2007:  Hedrick A.M. Davis, M.D., W. Lincourt, B.S., R. Trivedi, M.S., A. Ellsworth, B.S., C. Crim, M.D.Ventolin HFA: Safety In Children <48 Months Old Prepared abstract (Mar. 2007) NMA meeting A.M. Davis, M.D., W. Lincourt, B.S., R.Trivedi, M.S., A. Ellsworth, B.S., C.Crim, M.D Efficacy of Ventolin® HFA MDI Cumulative Dosing in Children <24 Months Old.. AAAAI Jan.2007 Shepard M.D., C Crim, M.D., R Trivedi, M.S., W Lincourt, B.S., A Ellsworth, B.S., AM Davis, M.D.Results of a randomized controlled trial on repeat albuterol dosing in acutely wheezing children <24 months old. J ACCP 2007 (May 2007) C.Crim, M.D., R.Trivedi, M.S., W. Lincourt, B.S., A. Ellsworth, B.S., A.M. Davis, M.D. Ventolin HFA MDI efficacy in children <24 months old in the acute care setting. abstract (Mar. 2007) NMA 2007 J. Hedrick, M.D., A.M. Davis, M.D., W. Lincourt, B.S., R. Trivedi, M.S., A.Ellsworth, B.S., C. Crim, M.D.Cardiac Safety Of Ventolin HFA In Children <48 Months Old. (Jan. 2007) AAAAI 2007 Hector Ortega, M.D., W. Lincourt, B.S., Amanda Emmett, Safety and Efficacy of Fluticasone propionate (FP) plus Salmeterol via a Single Device compared with Fluticasone propionate Alone in Patients Greater than or Equal to 50 Years of Age MS. American College of Chest Physicians: Chicago IL, October 20-25, 2007 J.P. Mitchell, PhD, H. MacKay, HBSc, M.W. Nagel, HBSc, K.J. Wiersema, BA, A.L. Cripps, PhD, S.M. Pischel, BSc and W.R. Lincourt, BS; In-vitro Performance of HFA Fluticasone Propionate (FP) in Two Valved Holding Chambers (Spacers) Tested with Facemasks Attached at Low Inspiratory Flow Rates and Extended Delay Times . American Academy of Allergy, Asthma & Immunology; March 14-18, 2008; Philadelphia, H. Ortega1 , D. Stempel1 , L. Sutton1 , W. Lincourt1 , L. Frith2 , R. Forth2 , W. Busse; on behalf of the GOAL Steering Committee3 ; 1 GlaxoSmithKline, RTP, NC, 2 GlaxoSmithKline, Stockley Park, UNITED KINGDOM, 3 University of Wisconsin School of Medicine, Madison, WI. Comparative Safety and Efficacy of Fluticasone Propionate plus Salmeterol via Diskus® Versus Fluticasone
Propionate in Subjects with Asthma Greater than or Equal to 55 and 65 Years of Age. AAAAI, 2008 Jolyon P. Mitchell1, Heather Mackay, Mark W. Nagel, Kimberly J. Wiersema, Alan L. Cripps, Sylvine M. Pischel2 and William R. Lincourt, IN-VITRO PERFORMANCE OF HFA FLUTICASONE PROPIONATE (FP) IN TWO VALVED HOLDING CHAMBERS (SPACERS) TESTED WITH FACEMASKS ATTACHED AT LOW INSPIRATORY FLOW RATES AND EXTENDED DELAY TIMES. ATS International Conference May 16 – 21, 2008, Toronto, Ontario Jolyon Mitchell, Mark Nagel, Kimberly Wiersema, Heather Mackay, Alan Cripps, Sylvine Pischel and William Lincourt, IN VITRO PERFORMANCE OF TWO VALVED HOLDING CHAMBERS (SPACERS) FOR PAEDIATRIC USE TESTED WITH FACEMASKS ATTACHED IS UNAFFECTED BY ROUTINE USE AND CLEANING. ERS, Annual Congress October 4 – 8, 2008, Berlin, Germany. HG Ortega AW Gilsenan, W Lincourt, RM Ziemiecki, C Lankevich, RH Stanford The Effect of Body Mass Index on Asthma Control: Results from the Asthma Control Characteristics and Prevalence Survey Study (ACCESS) AAAAI 2009 poster presentation RH Stanford, AW Gilsenan, W Lincourt, C Lankevich, RM Ziemiecki, DA Stempel, HG Ortega Predictors of Asthma Control: Results from the Asthma Control Characteristics and Prevalence Survey Study (ACCESS) AAAAI 2009 presentation. R H Stanford, PharmD, MS, A W Gilsenan, PhD, W Lincourt, MS, C Lankevich, MS, A Vanderpuije, MS2 and H G Ortega, MD, ScD1 Predictors of Asthma Control in Pediatric Asthmatics: Results from the Pediatric Asthma Control Characteristics and Prevalence Survey Study (ACCESS) ATS 2009. Kelly, H.W.; Lincourt, W; Kral, K.; Stempel;THE RELATIONSHIP BETWEEN FEF25-75 and FEV1 FOLLOWING TREATMENT WITH FLUTICASONE PROPIONATE OR FLUTICASONE PROPIONATE/SALMETEROL VIA DISKUS®2010 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI)

More Related Content

PDF
Outbreak Investigation
byPhilippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.
 
PPTX
Bioethics degree at new york
bymasterbioethics
 
PPTX
Master of bioethics
bymasterbioethics
 
DOC
Finished order 897226_1
byChris Kyeu
 
PPTX
K health ieeems2015
byPramod Anantharam
 
PPT
One health in india
byBhoj Raj Singh
 
PDF
Risks to-healthcare-workers
byPamelaRosaleschicago
 
PDF
Evaluating New Advances in Idiopathic Pulmonary Fibrosis and Other Interstiti...
byPVI, PeerView Institute for Medical Education
 
Outbreak Investigation
byPhilippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.
 
Bioethics degree at new york
bymasterbioethics
 
Master of bioethics
bymasterbioethics
 
Finished order 897226_1
byChris Kyeu
 
K health ieeems2015
byPramod Anantharam
 
One health in india
byBhoj Raj Singh
 
Risks to-healthcare-workers
byPamelaRosaleschicago
 
Evaluating New Advances in Idiopathic Pulmonary Fibrosis and Other Interstiti...
byPVI, PeerView Institute for Medical Education
 

What's hot

PDF
Outbreak Investigation of Healthcare Associated Infections
byPhilippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.
 
PDF
LinkedIn_JG_EnglishCV_ Jan 29 2016
byJanvier Gasana
 
PPS
Sepsis Congress 2011
byme_nasa
 
PPT
Antimicro
byJitendra Bhawalkar
 
PDF
2Chief Guest address
byohscmcvellore
 
PDF
Canadian clinical practice guidelines per il tarttamento delle rinosinusiti a...
byMerqurio
 
PDF
Cancer cell line panel screening
bysordidtheory3579
 
PDF
Top5 resp
byCharlotteSummers6
 
PDF
Gina 2012 report march13
byIrina Suley Tirado Perez
 
PDF
Gina 2012 1
byRiskadewi Agatha
 
PDF
Epidemiology and Hand Hygiene
byPhilippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.
 
Outbreak Investigation of Healthcare Associated Infections
byPhilippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.
 
LinkedIn_JG_EnglishCV_ Jan 29 2016
byJanvier Gasana
 
Sepsis Congress 2011
byme_nasa
 
Antimicro
byJitendra Bhawalkar
 
2Chief Guest address
byohscmcvellore
 
Canadian clinical practice guidelines per il tarttamento delle rinosinusiti a...
byMerqurio
 
Cancer cell line panel screening
bysordidtheory3579
 
Top5 resp
byCharlotteSummers6
 
Gina 2012 report march13
byIrina Suley Tirado Perez
 
Gina 2012 1
byRiskadewi Agatha
 
Epidemiology and Hand Hygiene
byPhilippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.
 

Similar to Professional Expericance

PPT
Asthma a clinical review and its management
byNani Karnam Vinayakam
 
PDF
Pediatric Slide Show
bygvcerv
 
PPT
Asthma_In_General_Practice_dec_2010.ppt
byPankajSharma956210
 
PPTX
pediatrics-asthma management _final_2019.pptx
byArun170190
 
PPT
Asthma in general practice dec 2010 (1)
byRichin Koshy
 
PPT
Smart therapy
byKhairul Jessy
 
PDF
Bronchial asthma.pdf for mbbs students lectures
byvinayaksrivastava511
 
PDF
Asthma_Medication.pdf
byRutvikShah52
 
PPTX
Pharmacological Management of Asthma
byPan London Airways Network
 
PPTX
Respiratory tract drugs
bySubham Kumar Vishwakarma
 
PDF
Updates On Pharmacological Management Of Asthma In Adults
byAshraf ElAdawy
 
PPTX
Asthma2020
byOlivier Downer
 
PPT
Clinical pharmacy in Pulmonology
byEneutron
 
PDF
Asthma In The 21st Century New Research Advances Rachel Nadif
bybotaokgallo
 
PPT
Asthma medications 9
byAmr Eldakroury
 
PPTX
Bronchial Asthma.pptx
bymulugeta asmamaw
 
DOCX
Case Study 21 Acute Asthma ManagementDifficulty
bysimisterchristen
 
PPT
Clinical pharmacy in pulmonology
byOyeleke Mary Oluwadunsin
 
PPT
Asthma
byRichin Koshy
 
PPTX
article jc p postgraduate examinationptx
bysujitha12341
 
Asthma a clinical review and its management
byNani Karnam Vinayakam
 
Pediatric Slide Show
bygvcerv
 
Asthma_In_General_Practice_dec_2010.ppt
byPankajSharma956210
 
pediatrics-asthma management _final_2019.pptx
byArun170190
 
Asthma in general practice dec 2010 (1)
byRichin Koshy
 
Smart therapy
byKhairul Jessy
 
Bronchial asthma.pdf for mbbs students lectures
byvinayaksrivastava511
 
Asthma_Medication.pdf
byRutvikShah52
 
Pharmacological Management of Asthma
byPan London Airways Network
 
Respiratory tract drugs
bySubham Kumar Vishwakarma
 
Updates On Pharmacological Management Of Asthma In Adults
byAshraf ElAdawy
 
Asthma2020
byOlivier Downer
 
Clinical pharmacy in Pulmonology
byEneutron
 
Asthma In The 21st Century New Research Advances Rachel Nadif
bybotaokgallo
 
Asthma medications 9
byAmr Eldakroury
 
Bronchial Asthma.pptx
bymulugeta asmamaw
 
Case Study 21 Acute Asthma ManagementDifficulty
bysimisterchristen
 
Clinical pharmacy in pulmonology
byOyeleke Mary Oluwadunsin
 
Asthma
byRichin Koshy
 
article jc p postgraduate examinationptx
bysujitha12341
 

Professional Expericance

  • 1.
    Professional Expericance Glaxo SmithKlineInc. RTP, North Carolina April 2001- Present Scientific Director Respiratory Medicine Development North American Medical Affairs Role requires a strong scientific and commercial understanding of the respiratory market as well as the ability to effectively communicate scientific information and develop clinical programs that support registration and promotion of respiratory medicine. Support US and global strategy for clinical development programs and regulatory submissions of new and marketed respiratory medicines. Develop phase II,-IV clinical studies. Extensive experience in areas of asthma disease progression, asthma management, HPA axis function, and device testing and specifications. Lead USMA Asset Scientist for FF/BREO. Member of FF/BREO asthma MMT and Launch strategy Teams. Member of the US Medical Affairs launch team for Flovent and Advair launches. Experienced in processing clinical and economic data for regulatory submission, publication, and formulary acceptance. Clinical lead for pediatric exclusivity for Ventolin and MDI dose counter programs. Prepare clinical sections of FDA briefing documents, Pediatric Study Plans (PSP) and EU Pediatric Investigation Plans (PIP). Medical Affairs scientist on Bioequivalence/Generic project team. Write, edit or review manuscripts, product monographs, sales training materials and promotional sales aids. Train sales staff and Regional Medical Scientists on key scientific data. Member of MMT, adult and pediatric asthma strategy teams, Clinical Lead for Study Conduct Teams and UMAP/program development working groups. Possess strong communication skills, ability to work across functional groups, knowledge of drug development and commercial as well as a good understanding of the competitive landscape. April 94 – April2001 Glaxo Wellcome, Inc. RTP, North Carolina Clinical Program Head Principal Clinical Research Scientist Respiratory Medical Affairs Project and program level management of phase IV clinical drug studies. Develop novel approaches to support product launch and promotional activities. Manage Contract Research Organizations conducting large multi-center clinical drug trials. Review and interpret clinical data and write/edit study reports, manuscripts, and abstracts. Forecast clinical budgets and manpower needs. Review and edit sales detail aids and physician teaching materials. Aug. 87 - April 94 Bristol-Myers Squibb Inc. Wallingford, Connecticut Senior Clinical Scientist - Infectious Diseases Clinical Scientist - Infectious Diseases Project management, clinical plan administration, protocol development, NDA support and review. Budget and resource negotiations. Supervise clinical trial monitored and
  • 2.
    oversee Contract ResearchOrganizations. Worked with 2nd and 3rd generation cephalosporins and anti-virals for claims in adults and children. Area of expertise includes upper and Oct. 83 - Aug. 87 Bristol-Myers Squibb Inc. Pharmaceutical Research Institute Wallingford, Connecticut Research Scientist Pre-clinical characterization of novel Antibiotic compounds. Evaluate data in support of the IND. Supervised one technician. Jan 82 - June 83 University of New York at Buffalo Medical School Buffalo, New York Research Technician - Infectious Diseases Research in the areas of antibiotic resistance, peptidoglycan structure and anaerobic bacterial growth. June 81 - Dec. 81 University of New York College at Buffalo Buffalo, New York Graduate Assistant Department of Biology Research in the area of host-parasite interactions Education Degree: Bachelor of Science in Biology May 1981. Salisbury University, Salisbury, MD 21801 Graduate School, 1981- 1983, State University of New York, College at Buffalo, Buffalo, NY Related Courses PhRMA Asthma Course PhRMA Clinical Study Management Course Effective Presentations Influence Management, Glaxo Wellcome 5-day management Core Technical Writing Management Leadership The Successful Negotiator Matrix Management Project Management Organizations/ Honors Beta Beta Beta National Biology Society, Omicron Delta Kappa National Honor Society Campus Life and Leadership Award- Salisbury University
  • 3.
    Publications Manuscripts Fung-Tomc, J.; LincourtW.; Thater C.; Kessler, R.; “Comparison of the Inhibitory and Bactericidal Activity of Aztreonam and Amikacin against Gram-Negative Aerobic Bacilli.” Annals of Clinical and Laboratory Science, Vol. 18, No. 6: 463-467, 1988. Raphael, G., Lanier, R.,Baker, J., Edwards, L., Rickard, K., Lincourt, W. “A Comparison Of Multiple Doses Of Fluticasone propionate and Beclomethasone dipropionate in subjects with persistent asthma” Journal of Allergy and Clinical Immunology., May 1999 Sorkness, C,. LaForce, C,. Storms, W,. Lincourt, W,. Edwards, L,. Rogenes, P,..“ The Effects of the Inhaled Corticosteroids Fluticasone propionate, Triamcinolone acetonide, and Flunisolide and oral Prednisone on the HPA-axis in Adult Asthmatics,”...Clinical Therapeutics, March 1999 Berger, W., Ford, L,. Mahr, T,. Nathan, R,. Crim, C,. Edwards, Lisa,. Wightman, D,. Lincourt, W,. Rickard, R,. “Efficacy and Safety of Fluticasone propionate 250mcg administered once daily in patients with persistent asthma treated with or without inhlaed corticosteroids.” Annals of Allergy, Asthma and Immunology Vol.89 Number 4, October 2002, pg. 393-399. Keton Sheth, MD; Jonathan A. Bernstein, MD; William R. Lincourt, BS; Kunal K. Merchant, PhD; Lisa D. Edwards, PhD; Courtney C. Crim, MD; Paul M. Dorinsky, MD, “Patient Perceptions of an Inhaled Asthma Medication administered as an Inhalation Powder via the DISKUS®™ or as an Inhalation Aerosol via a Metered Dose inhaler” Annals of Allergy, Asthma, & Immunology. 2003;91:55– 60. Jacqueline R. Carranza Rosenzweig, Lisa Edwards, William Lincourt, Paul Dorinsky and Richard L ZuWallack, “THE EFFECT OF LUNG FUNCTION AND DAILY SYMPTOMS ON ASTHMA QUALITY OF LIFE IN PATIENTS WITH PERSISTENT ASTHMA” Respiratory Medicine (2004) 98, 1157–1165 Courtney Crim, MD; Mark Holmes; Benjamin Lee, PharmD; Robb Cavanaugh; William Lincourt.,Evaluation of Particle Size Distribution of Ventolin HFA Administered via Metered Dose Inhaler With and Without Valved Holding Chambers, Annals of Allergy, Asthma, & Immunology. 94(1):80-85, January 2005. Nancy K. Ostrom, MD, Bruce A. Decotiis, MD, William R. Lincourt, BS, Lisa D. Edwards, Ph.D, Kathleen M. Hanson, BS, Jacqueline R. Carranza Rosenzweig, Pharm.D., Courtney Crim, MD, Comparative Efficacy and Safety of Low-Dose Fluticasone propionate and Montelukast in Children with Persistent Asthma, . Journal of Pediatrics August 2005. Richard L. Wasserman, MD; Ketan Sheth, MD; William R. Lincourt, BS; Nicholas W. Locantore, PhD; Jacqueline Carranza Rosenzweig, Pharm.D; Courtney Crim, MD Real World Assessment of a Metered Dose Inhaler with Integrated Dose Counter. Allergy & Asthma Proceedings 27:486 –492, 2006; .
  • 4.
    E.M. KERWIN, M.D.,M.M. TARPAY, M.D., K. KIM, M.D., M. J. NOONAN, M.D., W. LINCOURT, B.S., R. TRIVEDI, M.S., A. ELLSWORTH, B.S., A. DAVIS-ALLEN, M.D. Safety and Efficacy of a New Albuterol Hydrofluoroalkane Formulation for Treating Asthma Symptoms in Children 2 to Less than 4 Years of Age Pediatric Asthma, Allergy, and Immunology. Volume 19, Number 2, 2006. pp 81-90. K. SHETH, R. L. WASSERMAN, W. R. LINCOURT, N. W. LOCANTORE, J . CARRANZA- ROSENZWEIG, C. CRIM; Fluticasone propionate/salmeterol hydrofluoroalkane via metered- dose inhaler with integrated dose counter: performance and patient satisfaction Ltd Int J Clin Pract, October 2006, 60, 10, 1218–1224 James A. Hedrick, James W. Baker, Arthur B. Atlas, Aftab A. Naz, William R. Lincourt, Roopa Trivedi, Anna Ellworth and Angela M. Davis; Safety of Daily Albuterol in Infants with a History of Bronchospasm: A Multi-Center Placebo; Controlled Trial, The Open Respiratory Medicine Journal, 2009, 3, 100-106 Mintz M., Gilsenan A.W., Bui C.L., Ziemiecki R., Stanford R.H., Lincourt W., Ortega H;. Predictors of Asthma Control: Results from the Asthma Control Characteristics and Prevalence Survey Study (ACCESS) Current Medical Research and Opinion 2009 25:10 (2523- 2531) William Lincourt, Richard H Stanford, Alicia Gilsenan, Dana DiBenedetti and Hector Ortega; Assessing Primary Care Physician’s Beliefs and Attitudes of Asthma Exacerbation Treatment and Follow-up. The Open Respiratory Medicine Journal, 2010, 4, 9-15 9 Kaashmiri M., Shepard J., Goodman B., Lincourt W.R., Trivedi R., Ellsworth A., Davis A.M. Safety of daily albuterol in infants with a history of bronchospasm: A multi-center placebo controlled trial; Pediatric Emergency Care 2010 26:3 (197-202) Liu A.H., Gilsenan A.W., Stanford R.H., Lincourt W., Ziemiecki R., Ortega H. Status of asthma control in pediatric primary care: Results from the pediatric asthma control characteristics and prevalence survey study (ACCESS) Journal of Pediatrics 2010 157:2 (276-281.e3) Stanford R.H., Gilsenan A.W., Ziemiecki R., Zhou X., Lincourt W.R., Ortega H; Predictors of uncontrolled asthma in adult and pediatric patients: Analysis of the asthma control characteristics and prevalence survey studies (ACCESS). Journal of Asthma 2010 47:3 (257-262) Katial R.K., Bernstein D., Prazma C.M., Lincourt W.R., Stempel D.A. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. Allergy and Asthma Proceedings 2011 32:2 (127-136) Other Publications Murphy, T.; Lincourt, W.; “Studies on Mutants of Clostridium perfringens.” State University of New York Department of Medicine Research Conference, 1983.
  • 5.
    Fung-Tomc, J.; Lincourt,W.; Thater, C.; Kolek, B.; Huczkoe, E. Denbleyker, K.; and Kessler, R.; “In Vitro Activity of a New Fluoronapthyridone BMY 40062.” International Conference of Antimicrobial Agents and Chemotherapy, 1988. Jaurequi, L.; Lincourt W.; Doyle, C.; Tenney, J.; and Multi-Center Study Group. “Comparisons of Cefepime (FEP) and Ceftazidime (CAZ) for Treatment of Bacteremia and Sepsis - A Physiologic Analysis of Efficacy.” International Conference of Antimicrobial Agents and Chemotherapy, 1993. McCabe, R.; Farkas, S.; Lincourt W.’ Doyle, C.; and the Cefepime Multi-Center Study Group. “Efficacy Summary of International Experience with Cefepime (FEP) vs. Ceftazidime (CAZ) or Cefotaxime (CTX) for Pneumonia.” International Conference of Antimicrobial Agents and Chemotherapy, 1993. Galant, S.P.; Lincourt, W.; Rogenes, P.; Field, E. A.; Wisniewski, M. “Fluticasone Propionate Aqueous Nasal Spray versus Antihistamines for Sneezing and Nasal Itching.” American College of Allergists and Immunologists, 1994. Kapke, G.; Lincourt, W., “Immunochemical Versus HPLC Measurement of Serum Cortisol During A 6 Hour Cortrosyn Infusion In Steroid Naive Asthmatics” International Conference of the American Thoracic Society, May 1996. LaForce, C., Goldstein, M., Storms, W., Levy, B., Li, J., Littlejohn, T., McCluskey, D., Lincourt, W., Rogenes, P., Schaberg, A., Wisniewski, M., “Comparision of Inhaled Fluticasone Propionate And Flunisolide Effects on The HPA Axis As Assessed By The 6-Hour Cosyntropin Infusion Testing”. The European Resp. Journal, Vol 9, Supplement 23, Sept 1996. Sorkness, C., Howland, W., Stricker, W., Tita, J., Noveck, R., Dockhorn, R., Talbot, S., Lincourt, W., Rogenes, P., Schaberg, A., Wisniewski, M., “Comparision of Inhaled Fluticasone Propionate And Triamcinolone Acetonide Effects on The HPA Axis As Assessed By The 6-Hour Cosyntropin Infusion Testing”. The European Resp. Journal, Vol 9, Supplement 23, Sept 1996. Stroms, W., Howland WC., Sorkness CA., LaForce C., Goldstein , M., Lincourt, WR., Rogenes PR., Schaberg, AE., Edwards, L., “ Fluticasone Propionate, Triamcinolone Acetonide and Flunisolide have similar Effects on the HPA Axis. American Academy of Allergy Asthma and Immunology, March 1997. GD Raphael, JW Baker, P Chervinsky, J Grossman, MF Goldstein, , PR Rogenes, L Edwards, WR Lincourt, “Low Dose Fluticasone Propionate(FP) Is More Effective Than Higher Doses of Beclomethasone Dipropionate (BDP) In Patients With Mild To Moderate Asthma” American Academy of Allergy Asthma and Immunology, March 1998 JJ Murray, B Friedman, P Chervinsky, C Fogarty, JW Baker , PR Rogenes, L Edwards,.WR Lincourt,”Asthma Severity as a Determinant for Selecting Appropriate Doses of Fluticasone Propionate(FP) or Beclomethasone Dipropionate(BDP)” American Academy of Allergy Asthma and Immunology, March 1998
  • 6.
    JJ Murray, BFriedman, P Chervinsky, C Fogarty, JW Baker , PR Rogenes, L Edwards, WR Lincourt, “Fluticasone Propionate(FP) Is More Effective Than Higher Doses of Beclomethasone Dipropionate (BDP) In Patients With Moderate Asthma” International Conference of the American Thoracic Society, May 1998 Srebro SH, Rogenes PR, Edwards L, Lincourt WR: Comparison of efficacy and HPA effects of fluticasone propionate versus flunisolide in patients with mild to moderate asthma ;, Am J Respir Crit Care Med 1998; 157 (3): A406 C Crim, WR Lincourt, AL Stevens, TP Shah, LD Edwards, SM Harding, KA Rickard; Once- Daily Low Dose Fluticasone Propionate Diskus as Initial therapy in the Treatment of Adult Subjects with Persistent Asthma - A Subset Analysis of the Clinical Efficacy of Once-Daily dosing in Subjects with Mild-to-Moderate Asthma., American Academy of Allergy Asthma and Immunology, March 2000 Lisa D Edwards, Ken M Kral, James R Johnson, William R. Lincourt, A RETROSPECTIVE DESCRIPTIVE MEDICAL CLAIMS ANALYSIS OF INCREASED MEDICAL RISK IN ASTHMA MANAGEMENT FOR PATIENTS PRESCRIBED MONTELUKAST COMPARED TO FLUTICASONE PROPIONATE, American Academy of Allergy Asthma and Immunology, March 2001 Chervinsky P, Kalberg C, Goode-Sellers S, Edwards L, Lincourt W, Rickard K. A Comparison of Low Dose Fluticasone Propionate and Montelukast in Patients Stratified Based on Baseline Asthma Severity. Amer J Resp Crit Care Med; 163(5):A428, April 2001. Berger WE, Mahr TA, Crim C, Wightman DS, Edwards LD, Lincourt, WR, Rickard KA; Flovent 250mcg Administered Once Daily is Effective Initial Therapy in Patients with Persistent Asthma Currently Treated with Bronchodilators Alone, ACAAI in November 2001 Ford L, Crim C, Lincourt WR, Wightman D, Edwards LD, Rickard KA. Once Daily Low Dose Fluticasone Propionate In The Treatment Of Adult And Adolescent Subjects With Persistent Asthma Currently Using Low Doses Of Inhaled Corticosteroids. (AAAAI March 2002). K. K. Sheth, W. R. Lincourt, L. D. Edwards, P. Dorinsky, C. Crim; Patient Perceptions of an Inhaled Asthma Medication Administered as an Inhalation Powder via the Diskus or as an Aerosol via a Metered Dose Inhaler (AAAAI March 03) J.R.Carranza Rosenzweig, Pharm.D, M.S., L.D. Edwards, Ph.D , W.R .Lincourt, B.S. , R.H. Stanford, Pharm.D. and P.M. Jhingran, Ph.D. CORRELATION BETWEEN SYMPTOMS, LUNG FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH PERSISTENT ASTHMA, (International Conference of the American Thoracic Society May 2003)
  • 7.
    N.K.Ostrom, MD ,B.A.DeCotiis, MD , W.R.Lincourt, BS , L.D.Edwards, PhD and C. Crim, MD ; A Comparison of Low Dose Fluticasone Propionate and Montelukast in Children 6-12 Years of Age with Persistent Asthma. (International Conference of the American Thoracic Society May 2003) Courtney Crim, MD; Benjamin Lee, PharmD; William Lincourt; Mark Holmes, BSc (Hons ); and Robb Cavanaugh. GlaxoSmithKline, Inc., Research Triangle Park, NC, USA, IN-VITRO COMPARISON OF THE PERFORMANCE OF VALVED HOLDING CHAMBERS (VHC) FOR DELIVERY OF VENTOLIN® HFA INHALATION AEROSOL, (International Conference of the American Thoracic Society, May 2003) Carranza Rosenzweig, J; Lincourt, W ; Edwards, L ; Rickard, K; Cost-efficacy of Fluticasone Propionate Compared To Montelukast in the Treatment of Pediatric Asthma, (ACAAI 2003) W. R. Lincourt, C. Crim, K. M. Hanson, L. D. Edwards; Fluticasone Propionate (FP) was Superior to Montelukast (MON) in Producing at Least a 2-Step Improvement in Asthma Severity in Children 6-12 Years of Age. AAAAI, March 2004 (POSTER #348) C. Crim, M.D. , R. Trivedi , B. Lee , W. Wu, T. Weeks and W. Lincourt; Asthma Exacerbations Associated with Upper Respiratory Tract Infections in Asthmatic Children Under 4 years of Age Treated with Fluticasone Propionate . Poster Presentation at a Thematic Poster Session A53 Asthma Therapy (International Conference of the American Thoracic Society, May 2004) Courtney Crim, William Lincourt, Roopa Trivedi, Anna Ellsworth, Angela Davis-Allen,Ventolin HFA MDI, safety in children 24-<48 months old with asthma-like symptoms AAAAI, March 2005 Poster presentation. K.K. Sheth, MD, MBA , W.R. Lincourt, BS , B.T. Lee, Pharm. D2 , N.W. Locantore, Ph. D and C. Crim, MD; A Study to Evaluate the Handling Performance of Fluticasone Propionate/Salmeterol HFA MDI with Counter in Subjects with Asthma or COPD; American Thoracic Society, May 2005 poster presentation. Crim, Lincourt, Locantore, Rosenzweig, Handling Performance and Patient Satisfaction of a Metered Dose Inhaler(MDI) With Integrated Dose Counter in Patients With COPD. ACCP Chest meeting. ACCP – Poster- Montreal, Quebec, Canada Oct. 29-Nov. 3, 2005 Sheth K, Crim C, Carranza Rosenzweig J, Lincourt W, Locantore. Reliability and Patient Satisfaction with MDI with Dose Counter.Lincourt W, Poster- ACAAI - Anaheim, CA Nov. 5- 7, 2005 Sheth K, Lincourt W, Crim C, , Locantore W, Carranza Rosenzweig J. Patient Satisfaction with Fluticasone Propionate/Salmeterol (FSA) HFA with an Integrated Dose Counter. Poster- ERS - Copenhagen, Denmark Sept.17-21, 2005 Angela Davis, William Lincourt, Roopa Trivedi, et.al. Safety of Ventolin HFA MDI in Children Birth-<24 Months Old with Symptoms of Bronchospasm Presented at the Annual Meeting of American Academy of Allergy, Asthma and Immunology March 3-7, 2006 Miami Beach, FL
  • 8.
    Julie Shepard MD*Courtney Crim MD Roopa Trivedi MS William Lincourt BS Anna Ellsworth BS Angela Davis MD Ohio Pediatrics Inc., Huber Heights, OH RESULTS OF A RANDOMIZED CONTROLLED TRIAL ON REPEAT ALBUTEROL DOSING IN ACUTELY WHEEZING CHILDREN <24 MONTHS OLD, Pediatric presented at CHEST: Chest Medicine Wednesday, October 24, 2007 J. Hedrick, M.D., A.M. Davis, M.D., W. Lincourt, B.S., R. Trivedi, M.S., A.Ellsworth, B.S., C. Crim, M.D Cardiac Safety Of Ventolin HFA In Children <48 Months Old.. AAAAI Jan. 2007:  Hedrick A.M. Davis, M.D., W. Lincourt, B.S., R. Trivedi, M.S., A. Ellsworth, B.S., C. Crim, M.D.Ventolin HFA: Safety In Children <48 Months Old Prepared abstract (Mar. 2007) NMA meeting A.M. Davis, M.D., W. Lincourt, B.S., R.Trivedi, M.S., A. Ellsworth, B.S., C.Crim, M.D Efficacy of Ventolin® HFA MDI Cumulative Dosing in Children <24 Months Old.. AAAAI Jan.2007 Shepard M.D., C Crim, M.D., R Trivedi, M.S., W Lincourt, B.S., A Ellsworth, B.S., AM Davis, M.D.Results of a randomized controlled trial on repeat albuterol dosing in acutely wheezing children <24 months old. J ACCP 2007 (May 2007) C.Crim, M.D., R.Trivedi, M.S., W. Lincourt, B.S., A. Ellsworth, B.S., A.M. Davis, M.D. Ventolin HFA MDI efficacy in children <24 months old in the acute care setting. abstract (Mar. 2007) NMA 2007 J. Hedrick, M.D., A.M. Davis, M.D., W. Lincourt, B.S., R. Trivedi, M.S., A.Ellsworth, B.S., C. Crim, M.D.Cardiac Safety Of Ventolin HFA In Children <48 Months Old. (Jan. 2007) AAAAI 2007 Hector Ortega, M.D., W. Lincourt, B.S., Amanda Emmett, Safety and Efficacy of Fluticasone propionate (FP) plus Salmeterol via a Single Device compared with Fluticasone propionate Alone in Patients Greater than or Equal to 50 Years of Age MS. American College of Chest Physicians: Chicago IL, October 20-25, 2007 J.P. Mitchell, PhD, H. MacKay, HBSc, M.W. Nagel, HBSc, K.J. Wiersema, BA, A.L. Cripps, PhD, S.M. Pischel, BSc and W.R. Lincourt, BS; In-vitro Performance of HFA Fluticasone Propionate (FP) in Two Valved Holding Chambers (Spacers) Tested with Facemasks Attached at Low Inspiratory Flow Rates and Extended Delay Times . American Academy of Allergy, Asthma & Immunology; March 14-18, 2008; Philadelphia, H. Ortega1 , D. Stempel1 , L. Sutton1 , W. Lincourt1 , L. Frith2 , R. Forth2 , W. Busse; on behalf of the GOAL Steering Committee3 ; 1 GlaxoSmithKline, RTP, NC, 2 GlaxoSmithKline, Stockley Park, UNITED KINGDOM, 3 University of Wisconsin School of Medicine, Madison, WI. Comparative Safety and Efficacy of Fluticasone Propionate plus Salmeterol via Diskus® Versus Fluticasone
  • 9.
    Propionate in Subjectswith Asthma Greater than or Equal to 55 and 65 Years of Age. AAAAI, 2008 Jolyon P. Mitchell1, Heather Mackay, Mark W. Nagel, Kimberly J. Wiersema, Alan L. Cripps, Sylvine M. Pischel2 and William R. Lincourt, IN-VITRO PERFORMANCE OF HFA FLUTICASONE PROPIONATE (FP) IN TWO VALVED HOLDING CHAMBERS (SPACERS) TESTED WITH FACEMASKS ATTACHED AT LOW INSPIRATORY FLOW RATES AND EXTENDED DELAY TIMES. ATS International Conference May 16 – 21, 2008, Toronto, Ontario Jolyon Mitchell, Mark Nagel, Kimberly Wiersema, Heather Mackay, Alan Cripps, Sylvine Pischel and William Lincourt, IN VITRO PERFORMANCE OF TWO VALVED HOLDING CHAMBERS (SPACERS) FOR PAEDIATRIC USE TESTED WITH FACEMASKS ATTACHED IS UNAFFECTED BY ROUTINE USE AND CLEANING. ERS, Annual Congress October 4 – 8, 2008, Berlin, Germany. HG Ortega AW Gilsenan, W Lincourt, RM Ziemiecki, C Lankevich, RH Stanford The Effect of Body Mass Index on Asthma Control: Results from the Asthma Control Characteristics and Prevalence Survey Study (ACCESS) AAAAI 2009 poster presentation RH Stanford, AW Gilsenan, W Lincourt, C Lankevich, RM Ziemiecki, DA Stempel, HG Ortega Predictors of Asthma Control: Results from the Asthma Control Characteristics and Prevalence Survey Study (ACCESS) AAAAI 2009 presentation. R H Stanford, PharmD, MS, A W Gilsenan, PhD, W Lincourt, MS, C Lankevich, MS, A Vanderpuije, MS2 and H G Ortega, MD, ScD1 Predictors of Asthma Control in Pediatric Asthmatics: Results from the Pediatric Asthma Control Characteristics and Prevalence Survey Study (ACCESS) ATS 2009. Kelly, H.W.; Lincourt, W; Kral, K.; Stempel;THE RELATIONSHIP BETWEEN FEF25-75 and FEV1 FOLLOWING TREATMENT WITH FLUTICASONE PROPIONATE OR FLUTICASONE PROPIONATE/SALMETEROL VIA DISKUS®2010 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI)